scholarly article | Q13442814 |
P356 | DOI | 10.1038/SJ.BMT.1705751 |
P698 | PubMed publication ID | 17589530 |
P50 | author | Carlos A Ramos | Q38329408 |
Emel Gurkan | Q57840558 | ||
Richard E Champlin | Q89187648 | ||
Rima M Saliba | Q114428014 | ||
P2093 | author name string | de Lima M | |
Lichtiger B | |||
Anderson BS | |||
Patah PA | |||
P2860 | cites work | Clinical consequences of alterations in platelet transfusion dose: a prospective, randomized, double-blind trial | Q33329515 |
Platelet alloantibodies in transfused patients | Q33337692 | ||
Single donor versus pooled random donor platelet concentrates | Q33339326 | ||
The definition of refractoriness to platelet transfusions | Q33350432 | ||
Optimizing platelet transfusion therapy | Q33361167 | ||
Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients | Q33364823 | ||
Influence of antibiotics on posttransfusion platelet increment. | Q33497804 | ||
Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions | Q33501221 | ||
Intravascular and total body platelet equilibrium in healthy volunteers and in thrombocytopenic patients transfused with single donor platelets | Q33503019 | ||
Pooled platelet concentrates: maybe not fancy, but fiscally sound and effective | Q33581221 | ||
Single donor platelets: can we afford to use them? Can we afford not to use them? | Q33581227 | ||
Diagnosis and management of refractoriness to platelet transfusion | Q34494961 | ||
Selecting donors of platelets for refractory patients on the basis of HLA antibody specificity | Q48623928 | ||
Clinical consequences of alterations in platelet transfusion dose: a prospective, randomized, double-blind trial | Q73594688 | ||
Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness | Q73905982 | ||
Bleeding risk and platelet transfusion refractoriness in patients with acute myelogenous leukemia who undergo autologous stem cell transplantation | Q74249650 | ||
Clinical factors influencing posttransfusion platelet increment in patients undergoing hematopoietic progenitor cell transplantation--a prospective analysis | Q77302850 | ||
P433 | issue | 5 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | stem cell transplantation | Q65592366 |
P304 | page(s) | 461-464 | |
P577 | publication date | 2007-06-25 | |
P1433 | published in | Bone Marrow Transplantation | Q4941523 |
P1476 | title | Efficacy of prophylactic transfusions using single donor apheresis platelets versus pooled platelet concentrates in AML/MDS patients receiving allogeneic hematopoietic stem cell transplantation | |
P478 | volume | 40 |
Q37867952 | A general change of the platelet transfusion policy from apheresis platelet concentrates to pooled platelet concentrates is associated with a sharp increase in donor exposure and infection rates |
Q24186913 | A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation |
Q44720880 | Allergic transfusion reactions to platelets are more commonly associated with prepooled than apheresis components |
Q37508075 | Blood Product Supply in Germany: The Impact of Apheresis and Pooled Platelet Concentrates. |
Q37715077 | Blood still kills: six strategies to further reduce allogeneic blood transfusion-related mortality |
Q24187751 | Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation |
Q24186359 | Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation |
Q34791060 | Efficacy and Adverse Events of Platelet Transfusion Product-Specific Differences |
Q45995264 | Immunohematopoietic stem cell transplantation in Cape Town: a ten-year outcome analysis in adults. |
Q33417080 | Impact of platelet transfusion on toxicity and mortality after hematopoietic progenitor cell transplantation |
Q24197779 | Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation |
Q83305360 | [Use of platelet concentrates: a regional experience] |
Search more.